The 2024 iCMLf Goldman Prize is awarded to Professor Jeff H Lipton

In acknowledgment of his remarkable contributions to advancing clinical practice in CML, Professor Jeff H Lipton has been awarded the 2024 Goldman Prize. Professor Lipton is a world-renowned thought leader in CML, bone marrow failure syndromes as well as allogeneic stem cell transplant with a profound impact on patient care and advocacy. Until his retirement in December 2023, Jeff Lipton was Clinical Investigator at the Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto in Canada.

The iCMLf Goldman Prize honors individuals who have demonstrated extraordinary dedication and achievements in the management and treatment of CML.

‘Jeff has devoted his long-standing career to the care of CML patients.
Recognition with the iCMLf Goldman Prize is well deserved’ (Professor Franck Nicolini)

A Legacy of scientific excellence and compassionate care

At the heart of Professor Lipton's research is a commitment to advancing clinical research in CML and to the prevention and treatment of side effects associated with bone marrow transplantation.

His extensive clinical research spans phase I, II, and III trials for CML, focusing on targeted therapy approaches with TKIs and novel agents aimed at overcoming drug resistance. The second main aspect of his clinical career is dedicated to outcome analysis in allogeneic stem cell transplantation and the prevention of potential side effects. He is particularly interested in donor selection, graft types and therapy of chronic effects on patients beyond the initial post transplant period.

His compassionate approach to patient interaction, coupled with his unparalleled expertise in CML, has earned him widespread admiration and gratitude from patients and colleagues alike.

Jeff serves on the Unrelated Donor Transplant Advisory Board of OneMatch, Past President of the Canadian Bone Marrow Transplant Group (CBMTG), was an advisor to the Center for Research on Bone Marrow Transplantation (CIBMTR), has served on the Clinical Trials Group of the CBMTG, was Director of the Allogeneic Stem Cell Transplant Program at PMH, is Head of the CML Study Group at PMH. He sits on several International Advisory Boards relating to the therapy of CML including the International CML Foundation, ELN and the Canadian CML Guidelines Committee. In 2018, he received the Brian Druker Award Recognizing Extraordinary Care in CML given by the Canadian CML Network.

Throughout his career he has authored or co-authored more than 500 peer reviewed papers and 700 abstracts.

Jeff Lipton’s professional roles included that of a Clinical Investigator at the Princess Margaret Cancer Centre Cancer Clinical Research Unit (CCRU) and Professor of Medicine at the University of Toronto. He received a BSc in Biochemistry at the University of Calgary and went on to a PhD in Biochemistry at the University of Western Ontario. An MRC post-doctoral fellowship at the Weizmann Institute in Israel led to his developing interests in leukemia. He then went back to Calgary to go to medical school, followed by a residency in Internal Medicine. He then completed sub-specialty training in Medical Oncology at the University of Toronto and stayed on at the Princess Margaret Cancer Centre as a staff physician.

For more information about Professor Jeff Lipton’s work, please visit: https://www.uhnresearch.ca/researcher/jeffrey-h-lipton